145 related articles for article (PubMed ID: 17990708)
1. Management of rare diseases in respiratory medicine.
Johnson SR
Clin Med (Lond); 2007 Oct; 7(5):447-8. PubMed ID: 17990708
[No Abstract] [Full Text] [Related]
2. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
3. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
Harari S; Humbert M; Blasi F; Collard HR; Matucci-Cerinic M; Simonneau G; Vancheri C; Wells AU; Cottin V
Eur Respir Rev; 2015 Sep; 24(137):375-7. PubMed ID: 26324798
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the pulmonary involvement in the patient with tuberous sclerosis complex.
Roccatello D; Obert R; Sena GM; Longa L; Rossi D; Grosso E; Cavallo R; Sena LM; Giachino O; Migone N
Contrib Nephrol; 2001; (136):292-8. PubMed ID: 11688396
[No Abstract] [Full Text] [Related]
5. Pulmonary lymphangioleiomyomatosis.
Zhang X; Travis WD
Arch Pathol Lab Med; 2010 Dec; 134(12):1823-8. PubMed ID: 21128782
[TBL] [Abstract][Full Text] [Related]
6. Global effort against rare and orphan diseases.
Harari S; Cottin V; Humbert M
Eur Respir Rev; 2012 Sep; 21(125):171-2. PubMed ID: 22941880
[No Abstract] [Full Text] [Related]
7. The ERS guidelines for LAM: trying a rationale approach to a rare disease.
Johnson SR
Respir Med; 2010 Jul; 104 Suppl 1():S33-41. PubMed ID: 20451364
[TBL] [Abstract][Full Text] [Related]
8. [Pulmonary lymphangioleiomyomatosis with or without tuberous sclerosis].
Urban T
Rev Mal Respir; 2007 Jun; 24(6):725-40. PubMed ID: 17632432
[TBL] [Abstract][Full Text] [Related]
9. Why we should care about ultra-rare disease.
Harari S
Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
11. Statins in lymphangioleiomyomatosis: a word of caution.
El-Chemaly S; Taveira-DaSilva A; Stylianou MP; Moss J
Eur Respir J; 2009 Aug; 34(2):513-4. PubMed ID: 19648526
[No Abstract] [Full Text] [Related]
12. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary manifestations in tuberous sclerosis complex.
Gupta N; Henske EP
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):326-337. PubMed ID: 30055039
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.
Baldi BG; Radzikowska E; Cottin V; Dilling DF; Ataya A; Carvalho CRR; Harari S; Koslow M; Grutters JC; Inoue Y; Gupta N; Johnson SR
Chest; 2022 Jun; 161(6):1589-1593. PubMed ID: 34942174
[No Abstract] [Full Text] [Related]
15. [Lymphangioleiomyomatosis: an orphan disease in search for treatment].
Aruj PK
Medicina (B Aires); 2011; 71(4):402-4. PubMed ID: 21893460
[No Abstract] [Full Text] [Related]
16. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.
Paul E; Thiele E
N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966
[No Abstract] [Full Text] [Related]
17. Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis.
Kinoshita Y; Sakamoto A; Hidaka K
BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25326562
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
19. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
20. Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.
Terasaki Y; Yahiro K; Pacheco-Rodriguez G; Steagall WK; Stylianou MP; Evans JF; Walker AM; Moss J
Am J Respir Crit Care Med; 2010 Aug; 182(4):531-9. PubMed ID: 20413627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
